The managers of International Biotechnology Trust (IBT) have focused its portfolio in oncology, diseases of the central nervous system and rare diseases – areas where pricing pressure is less of an issue. This should cushion the trust as we approach election year and (as is usually the case in the US political cycle) threats to intervene in drug pricing create volatility in the biotech sector.
19 Sep 2019
Healthy yield attracts investors
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Healthy yield attracts investors
International Biotechnology Trust PLC (IBT:LON) | 627 0 0.0% | Mkt Cap: 236.9m
- Published:
19 Sep 2019 -
Author:
Ed Marten -
Pages:
18
The managers of International Biotechnology Trust (IBT) have focused its portfolio in oncology, diseases of the central nervous system and rare diseases – areas where pricing pressure is less of an issue. This should cushion the trust as we approach election year and (as is usually the case in the US political cycle) threats to intervene in drug pricing create volatility in the biotech sector.